Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Berberine vs VSL#3 / Visbiome: Berberine has the stronger overall evidence (7.5 vs 6.5/10); they're alternatives for inflammation-related symptoms — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Berberine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Helped
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
Top outcomes
A source-matched dose range is not available for this product and use.
With meals, Split into 2-3 doses
Berberine HCl capsules
A source-matched dose range is not available for this product and use.
The regimen depends on the exact preparation and treatment goal. Follow the treating team’s instructions rather than transferring a regimen between products, prevention and active disease.
Any time of day
Refrigerated sachet of the De Simone Formulation
and 3 more not shown
4-12 weeks
8-12 weeks
First 2 weeks
If on diabetes medications
9-12 months
12 months
8-12 weeks
n/a
Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis
Phytotherapy research : PTR (2025) · Meta-Analysis · n=1337
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials
Phytotherapy research : PTR (2023) · Meta-Analysis · n=1600
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
JAMA network open (2025) · RCT · n=113
The study included 113 patients with T2D (mean [SD] age, 54.3 [10.6] years; 72 male [63.7%]) who were randomized.
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Cochrane Database Syst Rev (2019) · Meta-Analysis
Chronic pouchitis maintenance: 85% (34/40) maintained remission at 9-12 months vs 3% (1/36) placebo — RR 20.24 (95% CI 4.28-95.81), low certainty
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gastroenterology (2000) · RCT · n=40
Relapse in 3/20 (15%) on the probiotic vs 20/20 (100%) on placebo, P<0.001
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Gut (2004) · RCT · n=36
Remission maintained at 1 year in 17/20 (85%) vs 1/16 (6%) placebo, p<0.0001
Each group's adjusted mean. Study A of PMID 18442638: 36 adults with newly diagnosed type 2 diabetes after 2 months of diet alone, randomised to berberine or metformin, 500 mg three times daily for 13 weeks. Completers only (berberine n=15, metformin n=16, 3 and 2 withdrew for treatment failure). Metformin is an active comparator, there is no placebo arm. Arm means are before and after treatment, not between-arm differences. The extractor had the two arms swapped: the abstract gives the berberine group as FBG 10.6 to 6.9 and HbA1c 9.5 to 7.5, which is the second column pair of Table 2 (headed Berberine, n=15). Source: PMID 18442638.
Each group's adjusted mean. Study A of PMID 18442638: 36 adults with newly diagnosed type 2 diabetes after 2 months of diet alone, randomised to berberine or metformin, 500 mg three times daily for 13 weeks. Completers only (berberine n=15, metformin n=16, 3 and 2 withdrew for treatment failure). Metformin is an active comparator, there is no placebo arm. Arm means are before and after treatment, not between-arm differences. The extractor had the two arms swapped: the abstract gives the berberine group as FBG 10.6 to 6.9 and HbA1c 9.5 to 7.5, which is the second column pair of Table 2 (headed Berberine, n=15). Source: PMID 18442638.
The 1,000 mg point is a placebo-controlled trial of berberine 1.0 g daily for 3 months in 116 people with type 2 diabetes, where HbA1c fell from 7.5% to 6.6% and fasting glucose fell more than on placebo (PMID 18397984). The 1,500 mg point is two trials of 500 mg three times daily: one in 36 people with new type 2 diabetes where glucose fell with no significant difference from metformin in this small pilot, with transient stomach side effects in 34.5% (PMID 18442638), and a placebo-controlled pilot in 34 people with prediabetes where HbA1c fell from 6.40% to 5.43% (PMID 37679692). No trial compared doses. The separate study observations do not establish a flat dose-response, an optimal dose or the response between them. Lower doses were not tested for glucose in any cited trial.
Berberine has a higher evidence score (7.5/10 vs 6.5/10) and wins in 2 of 3 categories.
Both Berberine and VSL#3 / Visbiome score equally (70) for inflammation-related symptoms.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
What genuinely lowers LDL/triglycerides — and why "red yeast rice" is a statin in disguise.
Berberine, inositol, magnesium vs the cinnamon/chromium hype — and the med-interaction warning.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.